Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NOS3 | P29474 | 1/20 | 0.37 |
| ▸ | NOS1 | P29475 | 1/20 | 0.37 |
| ▸ | NOS2 | P35228 | 1/20 | 0.37 |
| ▸ | CA1 | P00915 | 13/20 | 0.33 |
| ▸ | CA2 | P00918 | 13/20 | 0.33 |
| ▸ | CA12 | O43570 | 1/20 | 0.33 |
| ▸ | CA9 | Q16790 | 1/20 | 0.33 |
| ▸ | CHRNB2 | P17787 | 1/20 | 0.30 |
| ▸ | CHRNB4 | P30926 | 1/20 | 0.30 |
| ▸ | CHRNA3 | P32297 | 1/20 | 0.30 |
| ▸ | CHRNA4 | P43681 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1883327 | 0.88 | NOS3 (0.36) | NOS3NOS1NOS2CA1CA2 | |
| SCHEMBL26977407 | 0.85 | PDE4A (0.38) | NOS3NOS1NOS2 | |
| SCHEMBL3812152 | 0.85 | NOS3 (0.39) | NOS3NOS1NOS2CA1CA2 | |
| SCHEMBL28272895 | 0.84 | NOS3 (0.39) | NOS3NOS1NOS2CA1CA2 | |
| SCHEMBL623786 | 0.83 | NOS3 (0.33) | NOS3NOS1NOS2CA1CA2 | |
| Water SCHEMBL21810558 | 0.83 | NOS3 (0.38) | NOS3NOS1NOS2CA1CA2 | |
| SCHEMBL5326458 | 0.81 | NOS3 (0.37) | NOS3NOS1NOS2CA1CA2 | |
| SCHEMBL21404061 | 0.79 | CA1 (0.39) | NOS3NOS1NOS2CA1CA2 | |
| SCHEMBL941222 | 0.79 | ALDH1A1 (0.38) | NOS3NOS1NOS2CA1CA2 | |
| SCHEMBL346040 | 0.79 | NOS3 (0.36) | NOS3NOS1NOS2CA1CA2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 70 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230108723-A1 | Multi-Nutrient Composition | EXERKINE CORPORATION (CA) | 2023-04-06 | — | — | US | claimed |
| US-11504413-B2 | Multi-nutrient composition | EXERKINE CORPORATION (CA) | 2022-11-22 | — | — | US | claimed |
| US-10265317-B2 | Combination of creatine, an omega-3 fatty acid, and citicoline | UNIVERSITY OF UTAH RESEARCH FOUNDATION (US) | 2019-04-23 | — | — | US | claimed |
| US-20180263983-A1 | COMBINATION OF CREATINE, AN OMEGA-3 FATTY ACID, AND CITICOLINE | UNIV UTAH RES FOUND (US) | 2018-09-20 | — | — | US | claimed |
| WO-2018157258-A1 | MULTI-NUTRIENT COMPOSITION | EXERKINE CORPORATION (CA) | 2018-09-07 | — | — | WO | claimed |
| US-10058552-B2 | Combination of creatine, an omega-3 fatty acid, and citicoline | UNIVERSITY OF UTAH RESEARCH FOUNDATION (US) | 2018-08-28 | — | — | US | claimed |
| US-20170165264-A1 | COMBINATION OF CREATINE, AN OMEGA-3 FATTY ACID, AND CITICOLINE | UNIVERSITY OF UTAH RESEARCH FOUNDATION | 2017-06-15 | — | — | US | claimed |
| EP-3102227-A1 | COMBINATION OF CREATINE, AN OMEGA-3 FATTY ACID, AND CITICOLINE | University Of Utah Research Foundation (US) | 2016-12-14 | — | — | EP | claimed |
| CN-106102765-A | Combination of creatine, omega-3 fatty acid and citicoline | 犹他大学研究基金会 | 2016-11-09 | — | — | CN | claimed |
| WO-2015120299-A1 | COMBINATION OF CREATINE, AN OMEGA-3 FATTY ACID, AND CITICOLINE | UNIVERSITY OF UTAH RESEARCH FOUNDATION (US) | 2015-08-13 | — | — | WO | claimed |
| US-20130324609-A1 | DEPRESSION DISORDER THERAPEUTICS WITH CREATINE ANALOGS | UNIVERSITY OF UTAH RESEARCH FOUNDATION (US) | 2013-12-05 | — | — | US | claimed |
| WO-2012048243-A2 | DEPRESSION DISORDER THERAPEUTICS WITH CREATINE ANALOGS | UNIVERSITY OF UTAH RESEARCH FOUNDATION (US) | 2012-04-12 | — | — | WO | claimed |
| US-20110123654-A1 | SYNERGISTIC ENHANCEMENT OF CELLULAR ERGOGENIC NUTRIENT UPTAKE, LIKE CREATINE OR CARNITINE, WITH TARRAGON | FINZELBERG GMBH & CO. KG (DE) | 2011-05-26 | — | — | US | claimed |
| EP-2303040-A1 | SYNERGISTIC ENHANCEMENT OF CELLULAR ERGOGENIC NUTRIENT UPTAKE, LIKE CREATINE OR CARNITINE, WITH TARRAGON | PhytoLab GmbH & Co. KG (DE) | 2011-04-06 | — | — | EP | claimed |
| WO-2009147229-A1 | SYNERGISTIC ENHANCEMENT OF CELLULAR ERGOGENIC NUTRIENT UPTAKE, LIKE CREATINE OR CARNITINE, WITH TARRAGON | PHYTOLAB GMBH & CO. KG (DE) | 2009-12-10 | — | — | WO | claimed |
| US-7226947-B1 | Use of creatine as a fat substitute | ALZCHEM TROSTBERG GMBH (DE) | 2007-06-05 | — | — | US | claimed |
| CN-1224328-C | Use of creatine as fodder additive | DSM FINE CHEM AUSTRIA GMBH (AT) | 2005-10-26 | — | — | CN | claimed |
| EP-1176875-B1 | USE OF CREATINE AS A FEED SUBSTITUTE | DSM FINE CHEM AUSTRIA GMBH (AT) | 2005-01-19 | — | — | EP | claimed |
| CN-1350434-A | Use of creatine as fodder additive | DSM FINE CHEMICALS AUSTRIA (AT) | 2002-05-22 | — | — | CN | claimed |
| CN-112118855-B | Weight management composition | 爱瑟金股份有限公司 | 2026-05-12 | — | — | CN | disclosed |
| US-20260014220-A1 | Method for Treating Lysosomal Storage Disease | EXERKINE CORP (CA) | 2026-01-15 | — | — | US | disclosed |
| US-12419852-B2 | Method for treating lysosomal storage disease | EXERKINE CORPORATION (CA) | 2025-09-23 | — | — | US | disclosed |
| EP-4611786-A1 | FERTILITY ENHANCEMENT COMPOSITION | Exerkine Corporation (CA) | 2025-09-10 | — | — | EP | disclosed |
| US-12285456-B2 | Weight management composition | EXERKINE CORPORATION (CA) | 2025-04-29 | — | — | US | disclosed |
| CN-119403458-A | Water-soluble creatine agglomerates | 澳泽化学特罗斯特贝格有限公司 | 2025-02-07 | — | — | CN | disclosed |
| EP-3768290-B1 | WEIGHT MANAGEMENT COMPOSITION | EXERKINE CORP (CA) | 2024-08-21 | — | — | EP | disclosed |
| WO-2024092369-A1 | FERTILITY ENHANCEMENT COMPOSITION | EXERKINE CORPORATION (CA) | 2024-05-10 | — | — | WO | disclosed |
| US-20230201115-A1 | CREATINE AND/OR CREATININE COMPOSITIONS AND RELATED METHODS | THERMOLIFE INTERNATIONAL, LLC | 2023-06-29 | — | — | US | disclosed |
| US-11633354-B2 | Creatine and/or creatinine compositions and related methods | THERMOLIFE INTERNATIONAL, LLC (US) | 2023-04-25 | — | — | US | disclosed |
| US-20230108723-A1 | Multi-Nutrient Composition | EXERKINE CORPORATION (CA) | 2023-04-06 | — | — | US | disclosed |
| US-20230062170-A1 | CREATINE AND/OR CREATININE COMPOSITIONS AND RELATED METHODS | THERMOLIFE INTERNATIONAL, LLC | 2023-03-02 | — | — | US | disclosed |
| US-11504413-B2 | Multi-nutrient composition | EXERKINE CORPORATION (CA) | 2022-11-22 | — | — | US | disclosed |
| US-20220088040-A1 | Use of System XC-Inhibitor for Treating Statin-Induced Myalgia | EXERKINE CORP (CA) | 2022-03-24 | — | — | US | disclosed |
| US-20220062368-A1 | Weight Management Composition | MCMASTER UNIVERSITY (CA) | 2022-03-03 | — | — | US | disclosed |
| US-11167001-B2 | Weight management composition | EXERKINE CORPORATION (CA) | 2021-11-09 | — | — | US | disclosed |
| US-11154499-B2 | Creatine and/or creatinine compositions and related methods | THERMOLIFE INTERNATIONAL, LLC (US) | 2021-10-26 | — | — | US | disclosed |
| US-20210322358-A1 | Method for Treating Lysosomal Storage Disease | MCMASTER UNIVERSITY (CA) | 2021-10-21 | — | — | US | disclosed |
| CN-108929249-B | Synthetic process of ethyl creatine hydrochloride | 山东第一医科大学(山东省医学科学院) | 2021-10-08 | — | — | CN | disclosed |
| US-20210251895-A1 | CREATINE AND/OR CREATININE COMPOSITIONS AND RELATED METHODS | THERMOLIFE INTERNATIONAL, LLC | 2021-08-19 | — | — | US | disclosed |
| EP-3843716-A1 | METHOD FOR TREATING LYSOSOMAL STORAGE DISEASE | Exerkine Corporation (CA) | 2021-07-07 | — | — | EP | disclosed |
| EP-3768290-A1 | WEIGHT MANAGEMENT COMPOSITION | Exerkine Corporation (CA) | 2021-01-27 | — | — | EP | disclosed |
| CN-112118855-A | Weight management composition | 爱瑟金股份有限公司 | 2020-12-22 | — | — | CN | disclosed |
| US-20200246262-A1 | CREATINE AND/OR CREATININE COMPOSITIONS AND RELATED METHODS | THERMOLIFE INTERNATIONAL, LLC (US) | 2020-08-06 | — | — | US | disclosed |
| US-20200230197-A1 | MULTI-NUTRIENT COMPOSITION | EXERKINE CORP (CA) | 2020-07-23 | — | — | US | disclosed |
| WO-2020041871-A1 | METHOD FOR TREATING LYSOSOMAL STORAGE DISEASE | EXERKINE CORPORATION (CA) | 2020-03-05 | — | — | WO | disclosed |
| US-20190350997-A1 | Weight Management Composition | EXERKINE CORPORATIOIN (CA) | 2019-11-21 | — | — | US | disclosed |
| WO-2019191338-A1 | CREATINE AND/OR CREATININE COMPOSITIONS AND RELATED METHODS | THERMOLIFE INTERNATIONAL, LLC (US) | 2019-10-03 | — | — | WO | disclosed |
| US-20190298667-A1 | CREATINE AND/OR CREATININE COMPOSITIONS AND RELATED METHODS | THERMOLIFE INTERNATIONAL, LLC | 2019-10-03 | — | — | US | disclosed |
| WO-2019178689-A1 | WEIGHT MANAGEMENT COMPOSITION | EXERKINE CORPORATION (CA) | 2019-09-26 | — | — | WO | disclosed |
| WO-2019150323-A1 | SPORTS SUPPLEMENTS BASED ON LIQUID CREATINE | OSTOJIC SERGEJ (RS) | 2019-08-08 | — | — | WO | disclosed |
| US-10265317-B2 | Combination of creatine, an omega-3 fatty acid, and citicoline | UNIVERSITY OF UTAH RESEARCH FOUNDATION (US) | 2019-04-23 | — | — | US | disclosed |
| WO-2019071353-A1 | USE OF SYSTEM XC- INHIBITOR FOR TREATING STATIN-INDUCED MYALGIA | EXERKINE CORPORATION (CA) | 2019-04-18 | — | — | WO | disclosed |
| CN-108929249-A | A kind of new technique for synthesizing of ethyl creatine ester hydrochloride | 泰山医学院 | 2018-12-04 | — | — | CN | disclosed |
| US-20180263983-A1 | COMBINATION OF CREATINE, AN OMEGA-3 FATTY ACID, AND CITICOLINE | UNIV UTAH RES FOUND (US) | 2018-09-20 | — | — | US | disclosed |
| WO-2018157258-A1 | MULTI-NUTRIENT COMPOSITION | EXERKINE CORPORATION (CA) | 2018-09-07 | — | — | WO | disclosed |
| US-10058552-B2 | Combination of creatine, an omega-3 fatty acid, and citicoline | UNIVERSITY OF UTAH RESEARCH FOUNDATION (US) | 2018-08-28 | — | — | US | disclosed |
| US-20170165264-A1 | COMBINATION OF CREATINE, AN OMEGA-3 FATTY ACID, AND CITICOLINE | UNIVERSITY OF UTAH RESEARCH FOUNDATION | 2017-06-15 | — | — | US | disclosed |
| US-20170020834-A1 | PROPHYLACTIC USE OF NEUROPROTECTANTS IN SPORTS-RELATED TRAUMATIC BRAIN INJURY | NEUROLOGICS GROUP, LLC | 2017-01-26 | — | — | US | disclosed |
| EP-3102227-A1 | COMBINATION OF CREATINE, AN OMEGA-3 FATTY ACID, AND CITICOLINE | University Of Utah Research Foundation (US) | 2016-12-14 | — | — | EP | disclosed |
| CN-106102765-A | Combination of creatine, omega-3 fatty acid and citicoline | 犹他大学研究基金会 | 2016-11-09 | — | — | CN | disclosed |
| US-20160082065-A1 | PROPHYLACTIC USE OF NEUROPROTECTANTS IN SPORTS-RELATED TRAUMATIC BRAIN INJURY | NEUROLOGICS GROUP, LLC | 2016-03-24 | — | — | US | disclosed |
| WO-2015120299-A1 | COMBINATION OF CREATINE, AN OMEGA-3 FATTY ACID, AND CITICOLINE | UNIVERSITY OF UTAH RESEARCH FOUNDATION (US) | 2015-08-13 | — | — | WO | disclosed |
| US-20130324609-A1 | DEPRESSION DISORDER THERAPEUTICS WITH CREATINE ANALOGS | UNIVERSITY OF UTAH RESEARCH FOUNDATION (US) | 2013-12-05 | — | — | US | disclosed |
| WO-2012048243-A2 | DEPRESSION DISORDER THERAPEUTICS WITH CREATINE ANALOGS | UNIVERSITY OF UTAH RESEARCH FOUNDATION (US) | 2012-04-12 | — | — | WO | disclosed |
| US-20110123654-A1 | SYNERGISTIC ENHANCEMENT OF CELLULAR ERGOGENIC NUTRIENT UPTAKE, LIKE CREATINE OR CARNITINE, WITH TARRAGON | FINZELBERG GMBH & CO. KG (DE) | 2011-05-26 | — | — | US | disclosed |
| EP-2303040-A1 | SYNERGISTIC ENHANCEMENT OF CELLULAR ERGOGENIC NUTRIENT UPTAKE, LIKE CREATINE OR CARNITINE, WITH TARRAGON | PhytoLab GmbH & Co. KG (DE) | 2011-04-06 | — | — | EP | disclosed |
| WO-2009147229-A1 | SYNERGISTIC ENHANCEMENT OF CELLULAR ERGOGENIC NUTRIENT UPTAKE, LIKE CREATINE OR CARNITINE, WITH TARRAGON | PHYTOLAB GMBH & CO. KG (DE) | 2009-12-10 | — | — | WO | disclosed |
| US-7226947-B1 | Use of creatine as a fat substitute | ALZCHEM TROSTBERG GMBH (DE) | 2007-06-05 | — | — | US | disclosed |
| CN-1224328-C | Use of creatine as fodder additive | DSM FINE CHEM AUSTRIA GMBH (AT) | 2005-10-26 | — | — | CN | disclosed |
| CN-1350434-A | Use of creatine as fodder additive | DSM FINE CHEMICALS AUSTRIA (AT) | 2002-05-22 | — | — | CN | disclosed |
| CN-1350434-A | Use of creatine as fodder additive | DSM FINE CHEMICALS AUSTRIA (AT) | 2002-05-22 | — | — | CN | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (13 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20200246262-A1 | CREATINE AND/OR CREATININE COMPOSITIONS AND RELATED METHODS | MB, CKMT1A; CKMT1B, REN | NOS3 3285/4885NOS1 2779/4885NOS2 2173/4885 |
| US-11154499-B2 | Creatine and/or creatinine compositions and related methods | MB, CKMT1A; CKMT1B, REN | NOS3 3285/4885NOS1 2779/4885NOS2 2173/4885 |
| US-20190298667-A1 | CREATINE AND/OR CREATININE COMPOSITIONS AND RELATED METHODS | CKMT1A; CKMT1B, REN, ALB | NOS3 3810/4885NOS1 4018/4885NOS2 3880/4885 |
| US-20230201115-A1 | CREATINE AND/OR CREATININE COMPOSITIONS AND RELATED METHODS | CKMT1A; CKMT1B, REN, ALB | NOS3 4094/4885NOS1 4060/4885NOS2 3835/4885 |
| US-11633354-B2 | Creatine and/or creatinine compositions and related methods | MB, CKMT1A; CKMT1B, REN | NOS3 3285/4885NOS1 2779/4885NOS2 2173/4885 |
| US-20170165264-A1 | COMBINATION OF CREATINE, AN OMEGA-3 FATTY ACID, AND CITICOLINE | CHAT, CHKA, CRAT | NOS3 461/4885NOS1 2502/4885NOS2 2158/4885 |
| US-20230062170-A1 | CREATINE AND/OR CREATININE COMPOSITIONS AND RELATED METHODS | CKMT1A; CKMT1B, REN, ALB | NOS3 3810/4885NOS1 4018/4885NOS2 3880/4885 |
| US-10058552-B2 | Combination of creatine, an omega-3 fatty acid, and citicoline | CHAT, CHKA, CRAT | NOS3 461/4885NOS1 2502/4885NOS2 2158/4885 |
| US-10265317-B2 | Combination of creatine, an omega-3 fatty acid, and citicoline | CHAT, CHKA, CRAT | NOS3 461/4885NOS1 2502/4885NOS2 2158/4885 |
| US-20130324609-A1 | DEPRESSION DISORDER THERAPEUTICS WITH CREATINE ANALOGS | CKMT1A; CKMT1B, KYNU, AADAT | NOS3 2481/4885NOS1 2604/4885NOS2 2904/4885 |
| US-20210251895-A1 | CREATINE AND/OR CREATININE COMPOSITIONS AND RELATED METHODS | MB, CKMT1A; CKMT1B, REN | NOS3 3285/4885NOS1 2779/4885NOS2 2173/4885 |
| US-20260014220-A1 | Method for Treating Lysosomal Storage Disease | HADHB, LIPA, CPT1B | NOS3 2917/4885NOS1 3565/4885NOS2 3882/4885 |
| US-20180263983-A1 | COMBINATION OF CREATINE, AN OMEGA-3 FATTY ACID, AND CITICOLINE | CHAT, CHKA, CRAT | NOS3 461/4885NOS1 2502/4885NOS2 2158/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.